Prostate cancer is one of the major causes of cancerrelated death in the western world. Androgen-deprivation therapy (ADT) for the suppression of androgens binding to the androgen receptor (AR) has been the norm of prostate cancer treatment. Despite early success to suppress prostate tumor growth, ADT eventually fails leading to recurrent tumor growth in a hormonerefractory manner, even though AR remains to function in hormone-refractory prostate cancer. Interestingly, some prostate cancer survivors who received androgen replacement therapy had improved quality of life without adverse effect on their cancer progression. These contrasting clinical data suggest that differential androgen/ AR signals in individual cells of prostate tumors can exist in the same or different patients, and may be used to explain why ADT of prostate cancer fails. Such a hypothesis is supported by the results obtained from transgenic mice with selective knockout of AR in prostatic stromal vs epithelial cells and orthotopic transplants of various human prostate cancer cell lines with AR overexpression or knockout. These studies concluded that AR functions as a stimulator for prostate cancer proliferation and metastasis in stromal cells, as a survival factor of prostatic cancer epithelial luminal cells, and as a suppressor for prostate cancer basal intermediate cell growth and metastasis. These dual yet opposite functions of the stromal and epithelial AR may challenge the current ADT to battle prostate cancer and should be taken into consideration when developing new AR-targeting therapies in selective prostate cancer cells.
Introduction
Prostate cancer is the second leading cause of cancerrelated death among men in the United States (Jemal et al., 2005) . Approximately 80-90% of prostate cancers are dependent on androgens at initial diagnosis. Since the discovery by Huggins and Hodges (1941) that prostate cancer progression is influenced by androgen actions, androgen-deprivation therapy (ADT) to suppress androgens binding to androgen receptor (AR) remains the major treatment regimen for the disease (Denis and Griffiths, 2000) . However, ADT ultimately fails, and prostate cancer progresses to a hormonerefractory (androgen-independent) state with advanced metastasis and high morbidity and mortality.
Androgens function mainly through an axis involving the testicular synthesis of testosterone, its transport to target tissues (Roy et al., 1999) , and the conversion by 5a-reductase to the more active metabolite, 5a-dihydrotestosterone (Shimazaki et al., 1965; Anderson and Liao, 1968; Bruchovsky and Wilson, 1968) . Testosterone and 5a-dihydrotestosterone exert their biological effects through binding and transactivating AR (Heinlein and Chang, 2002; Heinlein and Chang, 2004; Rahman et al., 2004; Wang et al., 2005) , which involves interaction of AR with various coregulators during prostate development and prostate cancer progression (Heinlein and Chang, 2002; Rahman et al., 2004; Wang et al., 2005) .
AR is expressed throughout prostate cancer progression and its expression persists in the majority of patients with hormone-refractory disease (Cunha et al., 1987; Sadi et al., 1991; van der Kwast et al., 1991; Chodak et al., 1992; Hobisch et al., 1996; Mohler et al., 1996; Buchanan et al., 2001) , and many AR mutations identified from hormone-refractory prostate tumors are capable of transactivation. These observations suggest that the eventual failure of ADT cannot be attributed simply to the loss of AR function.
Prostate cancer patients undergoing ADT often develop hypogonadism, which is associated with sexual dysfunction, decreased lean body mass and muscle strength, increased adipocity, reduced quality of life, and osteoporosis. They also have a higher risk of developing metabolic syndrome, diabetes, and cardiovascular diseases (Basaria, 2008; Taylor et al., 2009) . Several studies have indicated that androgen replacement therapy (ART) of selected patients with castration-resistant prostate cancer led to improved quality of life without any adverse effect on their cancer progression for a considerable follow-up duration. Some of the selected patients even displayed a decrease in their serum prostate-specific antigen levels after ART (see details in section 'ART in prostate cancer patients'), indicating that there might be reduced cancer progression. However, the reasons behind the failure of ADT and why there are differential responses to androgen/ AR signals in different prostate cancer patients remain unclear at present.
We will use this review to present our hypothesis based on the recent findings and conclude that AR can function as both a proliferation stimulator and a tumor suppressor depending on its expression in individual prostatic cells to exert its diverse and differential functions for prostate cancer progression. These dual yet opposite functions of AR may thus create a direct challenge to the current ADT and promote new therapies in the battle against prostate cancer.
Human clinical studies with ADT and ART for prostate cancer-differential response to androgen/AR signaling
ADT in prostate cancer patients
The proliferation-stimulating function of AR is at the center of the premise for ADT in the treatment of prostate cancer (Huggins and Hodges, 1941) . ADT with either surgical or medical castration usually results in a response rate of 70-80% with a 12-33 months duration of progression-free survival . However, after an average of 24 months, the tumors almost always recur and no longer respond to ADT (Eisenberger et al., 1998) , even though the prostate tumors still express AR Mostaghel et al., 2007) . Interestingly, cell sorting of these ADT-refractory tumors found that the prostatic epithelial basal cell marker, cytokeratin 5 (CK5) (Bruchovsky et al., 1990; van Leender et al., 2001) increased from 29 to 75%, an observation consistent with the expansion of basal intermediate-like tumor cells observed in transgenic adenocarcinoma mouse prostate (TRAMP) mice with selective knockout of AR (ARKO) in prostatic epithelium (pes-ARKO-TRAMP) and inducible ARKO-TRAMP (ind-ARKO-TRAMP) mice (see details in section 'AR dual functions in prostate cancer progression and metastasis'). Recent clinical findings from 254 prostate cancer patients also indicated that the expression of nestin, which is linked to the metastatic potential of prostate cancer cells, is present only in the metastatic tumors of patients receiving ADT, suggesting that treatment with ADT might result in promotion of prostate metastatic tumors in these patients (Kleeberger et al., 2007) .
Together, these human clinical data suggest that ADT may be effective for prostate cancer patients only in selective prostate tumor cells and time periods, beyond which tumors will progress into the hormone-refractory stage with a more aggressive metastasis.
ART in prostate cancer patients
Several studies have shown that ART of hypogonadal patients with localized prostate cancer treated with radical prostatectomy or ADT has no adverse effect on prostate cancer progression (Kaufman and Graydon, 2004; Agarwal and Oefelein, 2005; Ferreira et al., 2006; Khera et al., 2009 ). Fowler and Whimore, (1981) observed that out of 52 metastatic prostate cancer patients who received ART, 45 exhibited increased cancer progression that could be reversed by androgen withdrawal, whereas 7 experienced symptomatic benefits. Other investigators have observed that in patients with castration-resistant metastatic prostate cancer, ART resulted in either little adverse effect on cancer progression or displayed some biochemical improvement or progression (Mathew, 2008; Morris et al., 2009; Szmulewitz et al., 2009) . These clinical studies suggested that prostate cancer patients have differential responses to androgen/AR signals and ART might be able to improve the quality of life in selective prostate cancer patients with little impact on further progression of their prostate cancers.
Differential androgen/AR signals in various prostate tumor cells from the same patient
The above clinical data led us to hypothesize that differential androgen/AR signals in individual cells of the prostate tumor might exist in the same or different patients, and may explain why ADT of prostate cancer fails. This hypothesis is supported by the isolation of three prostate primary tumor lines, PCa1, PCa2, and PCa3, from the same patient that exhibited differential responses to the androgen/AR signals after orthotopic implantation into androgen-supplemented vs castrated SCID mice (Figure 1 ) (Wang YZ, unpublished data) . Although both PCa1 and PCa2 cells express AR and prostate-specific antigen, PCa1 cells grew more rapidly, whereas PCa2 cells grew more slowly in castrated than in androgen-supplemented mice, suggesting that they are androgen-suppressed and androgenstimulated tumor cells, respectively. In contrast, the growth of PCa3 cells was similar in castrated vs androgen-supplemented mice, indicating that it is androgen insensitive. These various responses of prostate cancer cells to androgen/AR signals from the same patient are very similar to the responses of hair follicles to androgen/AR signals from the same person (Inui et al., 2002) : positive for the hair follicles in the mustache area, negative for the hair follicles on the top of the skull, toward the front, and independent for the hair follicles on the back of the head. These contrasting effects of androgen/AR signals in the prostate tumor cells or hair follicles from the same person (Figure 2 ) strengthen our hypothesis that differential androgen/AR signals exist in various cells of prostate tumors to explain why ADT of prostate cancer fails.
The following sections will summarize various in vitro and in vivo evidences from mice and human prostate cancer cell lines to support such a conclusion.
AR dual functions in prostate cancer progression and metastasis
Recent studies using epithelial-specific, fibroblast-specific, and smooth muscle-specific ARKO mice have indicated that during prostate development, AR in stromal cells functions as a proliferation stimulator, whereas AR in epithelial basal intermediate cells functions as a suppressor, and in epithelial luminal cells functions as a survival factor. (The detailed descriptions of these AR dual functions in normal prostate development are described in Supplementary Information). Here, we will focus on discussion of the similar dual AR functions in prostate cancer progression and metastasis. Huggins and Hodges (1941) provided the first solid in vivo evidence for androgen/AR signals to function as a proliferation stimulator for prostate cancer progression, which became a common view supported by the subsequent ADT for treating prostate cancer patients with early success. Nevertheless, how and in which cell(s) AR may function as a proliferation stimulator of cancer cells remain unclear. Here, we summarize recent findings that suggest AR in stromal cells might function as a stimulator, whereas AR in epithelial luminal-like cells might function as a survival factor, and in epithelial basal intermediate-like cancer cells, AR might function as a suppressor of prostate cancer progression and metastasis.
AR in stromal cells: a stimulator for tumor progression and metastasis Stromal-epithelial interaction remains important for tumor progression and metastasis (Cunha et al., 2003; Bhowmick and Moses, 2005; Condon, 2005) . During tumor progression, the stromal cells, including fibroblasts, myofibroblasts, endothelial, and immune cells, form a AR dual functions in prostate cancer therapy Y Niu et al microenvironment supporting the progression, survival, and metastasis of the tumor. In the normal human prostate, the stroma is constituted mainly of smooth muscle cells expressing AR. In prostatic carcinoma, the tumor stroma is constituted mainly of fibroblastic and myofibroblastic cells (Cunha et al., 2003) , suggesting that cell-transition changes have occurred in both the stroma and the epithelium during tumorigenesis. Earlier tissue recombination studies by Thompson et al. (1993) have indicated that prostatic tumorigenesis indeed requires changes in both the stroma and the epithelium, a notion supported by the results of Cunha and co-workers (Olumi et al., 1999; Wang et al., 2001; Cunha et al., 2003; Ricke et al., 2006) . Thus, prostate cancer-associated fibroblasts could promote tumor transformation of the epithelial BPH-1 cells that are immortalized with SV40 Tag (Olumi et al., 1999; Wang et al., 2001) . Similarly, urogenital mesenchymes from rat and mouse could also elicite tumor transformation in BPH-1 cells in the presence of testosterone and 17b-estradiol (E2) (Wang et al., 2001; Ricke et al., 2006) . However, cancer-associated fibroblasts in a castrated host and urogenital mesenchyme from testicular feminized mice (a mouse without functional AR) were unable to promote tumor transformation from BPH-1 cells (Ricke WA, personal communication) . In addition, knockdown of AR in cancer-associated fibroblasts isolated from tumors of TRAMP mice reduces their ability to promote BPH-1 colony formation in soft agar (Chang C et al., unpublished data). These observations indicate that the stromal AR is required for prostate tumor development.
AR-negative epithelial PC-3 cells were co-cultured with human prostatic stromal WPMY1-v or WPMYARsi cells (Niu et al., 2008a) to investigate the function of the stromal AR in tumor progression and metastasis. The results from the co-culture system indicated that knockdown of AR in WPMY1-ARsi cells resulted in the co-cultured PC-3 cells being less invasive in a Boyden chamber invasion assay than PC-3 cells with vectortransfected WPMY1-v cells (Niu et al., 2008a) . After orthotopic inoculation in nude mice, PC-3 cells also produced smaller primary and pelvic lymph node (PLN) metastatic tumors when combined with WPMY1-ARsi than with WPMY1-v cells (Niu et al., 2008b) . Similar in vivo androgen/AR-dependent tumor growth were also observed using other AR-negative prostate cancer cell lines (Marques et al., 2005; Halin et al., 2007) , and LNCaP cells might grow more aggressively on orthotopic transplantation after being co-inoculated with rat urogenital mesenchyme or bone marrow fibroblasts (Gleave et al., 1991) . Together, these in vitro and in vivo findings suggested that the stromal AR might function as a proliferation stimulator to promote prostate tumor progression and metastasis.
AR in epithelial cells: an anti-apoptosis survival factor and a suppressor of proliferation for cancer epithelial cells The TRAMP mouse model is a prostate cancer model that develops prostate tumors spontaneously at 10-12 weeks of age (Gingrich et al., 1991) . TRAMP mice were mated with the floxed AR transgenic mice to obtain TRAMP mice carrying the floxed AR transgene, which in turn were crossed with probasin-Cre mice to generate prostate epithelial-specific (pes)-ARKO-TRAMP mice (Niu et al., 2008a, b) . Prostatic epithelial cells develop from stem cells through proliferation and differentiation into basal and intermediate cells that finally differentiate into epithelial luminal cells (Litvinov et al., 2003; Tokar et al., 2005) . AR is expressed in about 50% of the basal cells and all of the luminal cells in mouse prostate (Mirosevich et al., 1999; Niu et al., 2008a) . Similar to pes-ARKO mice , knocking out AR from these epithelial cells in pes-ARKO-TRAMP mice and others resulted in increased apoptosis of CK8-positive epithelial luminal cells (18%) as compared with those (2%) from wild-type TRAMP mice at 16 weeks of age (Niu et al., 2008a) , suggesting that AR in the epithelial luminal cells may function as a survival factor to protect prostate cancer cells from apoptosis.
However, knocking out the epithelial AR in pes-ARKO-TRAMP mice also resulted in increasing numbers of proliferating cells in CK5-positive-basal cells, including the CK5/CK8-double-positive-basal intermediate cells. The consequence of increased apoptosis in luminal cells and increased proliferation in basal intermediate cells then resulted in less differentiated yet larger primary tumors in the ventral prostate of pes-ARKO-TRAMP mice than tumors from 16-week-old TRAMP mice (Niu et al., 2008b) . The primary prostate tumors of pes-ARKO-TRAMP mice exhibited a higher population of CD44-positive (Liu et al., 2004; Bhatia et al., 2005) and CK5/CK8-positive (van Leenders and Schalken, 2003; Bhatia et al., 2005) intermediate-like cells than those found in wild-type TRAMP mice (Niu et al., 2008a) . Incidentally, CD44-positive, but ARnegative prostate cancer cells purified from human prostate cancer xenografts were also enriched in tumorigenic and metastatic progenitor cells (Patrawala et al., 2006) . These results indicated knocking out the epithelial AR might lead to cell population changes with expansion of intermediate-like tumor cells and decreased secretory luminal cells in the prostates of pes-ARKO-TRAMP mice (Niu et al., 2008a) . These results suggested that epithelial AR might function as a proliferation suppressor in epithelial basal intermediate cells and a survival factor in epithelial luminal cells. As prostate carcinoma arises from epithelial cells, the opposite functions of the epithelial AR in different epithelial cells could then affect prostate cancer progression in TRAMP mice by favoring survival of differentiated tumor epithelium while suppressing proliferation of epithelial basal intermediate cells, thereby retarding tumor progression to a more malignant stage.
AR in epithelial cells: a suppressor of prostate cancer metastasis
The AR signals in prostate cancer epithelial cells also influence tumor metastasis. Thus, the size of metastatic tumors in PLNs of pes-ARKO-TRAMP mice was larger than those from wild-type TRAMP littermates at the age of 24 weeks. In addition, more prostate cancer metastatic foci were observed within the livers of pes-ARKO-TRAMP than in TRAMP mice (Niu et al., 2008a) . AR-negative PLN metastatic tumor isolated from pes-ARKO-TRAMP mice was more invasive than those from TRAMP mice in vitro. Importantly, restoring the expression of AR by transfection could reduce the invasiveness of PLN tumors from pes-ARKO-TRAMP mice (Niu et al., 2008a ). An early study also found that poorly differentiated PLN metastatic tumors in castrated TRAMP mice were more aggressive than tumors from intact TRAMP mice (Gingrich et al., 1991) . Therefore, it may be concluded that the epithelial AR also functions as a suppressor of prostate tumor invasion and metastasis.
Relative influences of the stromal and epithelial AR on prostate cancer progression and metastasis The ind-ARKO-TRAMP (Niu et al., 2008b) mice were then produced to assess the consequence of simultaneously knockdown of both the stromal and epithelial AR that have opposite functions in prostate cancer progression and metastasis. The knockout AR in ind-ARKO-TRAMP mice is mediated by Mx1-Cre, which is interferon inducible and can be activated by injection of polyinosinic-polycytidic acid to induce endogenous interferon and thus activate the Cre recombinase in various tissues (Ku¨hn et al., 1995) including the prostate Niu et al., 2008b) . After injection of polyinosinic-polycytidic acid in 12-week-old mice, AR mRNA expression in the prostate was found knocked down by 50% in the stroma and 60% in the epithelium in 16-week-old ind-ARKO-TRAMP mice compared with polyinosinic-polycytidic acid-injected control TRAMP mice. Knocking down prostatic AR expression at this early stage resulted in smaller and lessdifferentiated primary prostate tumors in ind-ARKO-TRAMP than in the control TRAMP mice through 16-24 weeks of age. The tumors of ind-ARKO-TRAMP mice had lower proliferation rates and higher apoptosis rates than tumors of the control TRAMP mice. Moreover, the tumors of ind-ARKO-TRAMP mice had decreased CK8-positive luminal-like cells and increased CK5-and CD44-positive-basal cells and CK5/CK8-double-positive-basal intermediate-like cells than tumors of the control TRAMP mice (Niu et al., 2008b) .
Despite the fact that both pes-ARKO-TRAMP and ind-ARKO-TRAMP mice had higher epithelial luminal cell apoptosis and expansion of basal intermediate-like cells, pes-ARKO-TRAMP mice produced larger PLN metastatic tumors, whereas knocking down AR at an early stage in ind-ARKO-TRAMP mice produced smaller metastatic tumors than the control mice. These contrasting observations suggest that the stromal AR may have more dominant functions during prostate cancer progression at an early stage.
Metastatic tumors were also compared at the time when primary tumors had reached 1 cm 2 in TRAMP (20 weeks), pes-ARKO-TRAMP (18 weeks), and ind-ARKO-TRAMP (36 weeks) mice. The welldifferentiated tumors of TRAMP mice developed small metastatic tumors in the PLN. The poorly differentiated tumors of pes-ARKO-TRAMP mice developed much larger PLN metastatic tumors and metastasized into multiple organs, whereas those of ind-ARKO-TRAMP mice were smallest and they metastasized into the seminal vesicle and liver. Thus, loss of the epithelial AR promotes prostate cancer progression and metastasis as shown in pes-ARKO-TRAMP, whereas concurrent knockdown of the stromal and epithelial AR at an early stage can override these effects of the epithelial ARKO, thereby retarding growth of the tumor and suppressing their metastasis as shown in ind-ARKO-TRAMP mice. More importantly, ind-ARKO-TRAMP mice with early knockdown of prostatic AR had longer survival time than wild-type TRAMP and pes-ARKO-TRAMP mice (Niu et al., 2008b) . However, the dominance of the stromal AR over the epithelial AR function diminished when ARKO in ind-ARKO-TRAMP mice was induced after the primary tumor has progressed for some time. Thus, when knockdown of AR in ind-ARKO-mice was induced at 20 weeks of age (and not at 12 weeks of age as mentioned above), the sizes of primary and PLN metastatic tumors developed after 24 weeks of age were similar between ind-ARKO-TRAMP and TRAMP mice, suggesting that the relative influences of the stromal and epithelial AR signals on prostate cancer progression and metastasis can vary with the progression of the tumor (Niu et al., 2008b) .
Together, these observations not only support the notion that the epithelial AR functions as a tumor suppressor for prostate cancer progression and metastasis, but also indicate that the stromal AR may function as a stimulator of the prostate cancer progression and metastasis.
Dual AR functions in human prostate cancer cell lines
The dual yet opposite AR functions to influence prostate cancer cell proliferation and metastasis are also confirmed in various human prostate cancer cell lines as follows.
PC-3 cells: AR functions as suppressor of proliferation and metastasis
The PC-3 cell line was originally isolated from a human bone marrow prostate metastastic tumor (Kaighn et al., 1979) . PC-3 cells express CK5 and CK8/18, but not AR. To test whether AR in PC-3 cells may also function as both stimulator and suppressor observed in mouse models, the growth, invasive, and metastatic properties of PC-3 cells carrying the empty vector (PC-3-v cells) and PC-3-AR9 cells were compared. PC-3-AR9 cells were found less invasive in an in vitro invasion assay and produced less osteolytic lesions in a bone-wafer resorption assay than PC-3-v cells (Niu et al., 2008a) . When these cells were inoculated into the tibia of athymic nude mice, it was found that PC-3-v tumors grew more invasively and aggressively than PC-3-AR9 tumors, suggesting that knockin of a functional human AR in PC-3 cells resulted in suppression of their invasion in vitro and in vivo.
Furthermore, PC-3-v or PC-3-AR9 cells were orthotopically injected into the anterior prostate of nude mice. Consistent with the above findings, mice injected with PC-3-v cells developed bigger prostate primary tumors that were less differentiated (Niu et al., 2008b) and larger PLN metastatic tumors (Niu et al., 2008a) than mice inoculated with PC-3-AR9 cells. Moreover, when PC-3-v or PC-3-AR9 cells were co-cultured with WMPY1 stromal cells (Webber et al., 1999) and orthotopically transplanted in nude mice, PC-3-AR9 co-cultured cells still produced smaller primary and metastatic tumors than PC-3-v co-cultured cells, suggesting that even in the presence of stromal AR stimulation, the suppressor function of the epithelial AR remains effective. Using transfectants of PC-3 cells with an inducible AR-expressing transgene, Nelius et al. (2007) also observed that induction of AR expression in an inducible PC-3-AR þ line resulted in an androgendependent decrease in invasion in vitro and decreased tumorigenecity because of decreased microvascular density that led to increased tumor cell apoptosis after subcutaneous inoculation in nude mice.
Together, these results showed that loss of prostatic epithelial AR results in the development of more invasive and metastatic prostate tumors and gainof-AR function reverses these characteristics. Thus, the above human prostate cancer cell observations are consistent with pes-ARKO-TRAMP mice data and strongly indicate that prostatic epithelial AR functions as a suppressor of prostate tumor growth and metastasis.
LNCaP cells: AR could function as proliferation stimulator and suppressor
The LNCaP cells, which were isolated from a lymph node prostate metastatic tumor (Horoszewicz et al., 1983) and express a mutated AR(T877A) (Veldscholte et al., 1990) , are CK5-negative and CK8/18-positive and thus are luminal-like tumor cells (van Bokhoven et al., 2003) . These cells may respond to androgen/AR signals differentially depending on different environments (Olea et al., 1990) and exhibited variants. For example, the ARexpressing LNCaP-FGC and LNCaP-LNO cell lines isolated from the same lymph node metastatic tumor (Horoszewicz et al., 1983) exhibited different and opposite proliferation responses toward androgen (Olea et al., 1990 , Soto et al., 1995 . Proliferation of LNCaP-FGC cells was stimulated by a low concentration and suppressed by a high concentration of androgen, whereas proliferation of LNCaP-LNO cells was suppressed by physiological concentrations of androgen. These different cell phenotypes might represent adaptive changes in prostate cancer cells during tumor progression.
The differential responses to androgen seen in various LNCaP cells was confirmed later using androgendependent LNCaP cells that were cultured in long-term absence of androgen (Kokontis et al., 1994) or after prolonged numbers of passages (480) (Igawa et al., 2002) to develop sublines with androgen-independent proliferation. Addition of androgen to these androgenindependent variants of LNCaP cells suppressed proliferation (Kokontis et al., 1998) and promoted apoptosis (Joly-Pharaboz et al., 2000) . Such adaptive changes from growth stimulator to suppressor have also been observed in LNCaP xenografts in vivo after castration of the host (Thalmann et al., 2000; Zhou et al., 2004; Chuu et al., 2006) . Down-regulation of AR with anti-sense oligonucleotides (Eder et al., 2000) or siRNA (Ha˚a˚g et al., 2005; Liao et al., 2005) may result in the suppression of cell proliferation or promotion of apoptosis in both androgen-dependent and androgen-independent sublines of LNCaP cells. Eder et al. (2002) found that an AR-specific anti-sense oligonucleotide could suppress the growth of LNCaP xenografts. Down-regulation of the AR (through siRNA) in LNCaP cells also suppressed their invasion in vitro (Chang C et al., unpublished data) .
Interestingly, recurrent androgen-independent tumors developed from orthotopic primary tumors of LNCaP cells after castration of SCID mice hosts exhibited increased proliferation and decreased apoptosis compared with the androgen-dependent primary tumors of LNCaP cells, a change that is associated with decreased AR protein expression (Zhou et al., 2004) . Thus, it seems that once progressed to androgen-independent state in vivo, LNCaP cells might be relieved from epithelial AR suppression because of down-regulation of the AR.
CWR22Rv1 cells: AR functions as proliferation stimulator and suppressor
The CWR22Rv1 prostate cancer cell line, derived from a recurrent tumor (Nagabhushan et al., 1996) after ADT of a CWR22 xenograft originally established from a human prostate primary tumor (Wainstein et al., 1994) , is an AR and CK8/18-expressing tumor cell line (van Bokhoven et al., 2003) . CWR22rv1-AR þ /À cells were generated after knocking down AR in CWR22rv1 cells by genomic recombination. CWR22rv1-AR þ /À cells expressed much less AR with negligible AR transactivation and displayed suppressed growth rate compared with the parental CWR22rv1-AR þ / þ cells (Chang et al., paper in preparation). In contrast, CWR22rv1-AR þ /À cells produced bigger primary and PLN metastatic tumors than CWR22rv1-AR þ / þ cells on orthotopic transplantation (Niu et al., paper in preparation) , suggesting that the AR functions observed in cell lines in vitro might not accurately represent the AR functions in vivo.
CWR22rv1-AR þ /À cells were more invasive than the parental cells in vitro. Using an AR-specific siRNA to knockdown the AR in CWR22rv1-AR þ / þ cells also rendered the resultant CWR22rv1-AR þ / þ -ARsi cells more invasive than the parental cells transfected with scrambled RNA (Niu et al., 2008a) , whereas expression of a functional human AR in CWR22rv1-AR þ /À cells through a retroviral vector rendered the CWR22rv1-AR þ /À -human AR cells less invasive than the parental cells transfected with the empty vector (Niu et al., 2008a) . Together, these observations support the notion that the AR in prostatic cancer epithelial cells functions as a suppressor of prostate cancer metastasis.
PC346C cells: AR functions as proliferation stimulator and suppressor PC346C, established from a human primary tumor through xenograft (van Weerden et al., 1996; van Weerden and Romijn, 2000) , is an androgen-dependent prostate cancer cell line expressing wild-type AR and CK8/18 (van Bokhoven et al., 2003) . After long-term androgen ablation, another androgen-independent subline, PC346DCC, with a 95% decrease in AR expression, was generated from PC346C cells. On orthotopic transplantation, PC346DCC tumors grew more rapidly in intact than in castrated hosts, suggesting stromal influence in addition to androgenindependent growth (Marques et al., 2005) . Treatment of PC346C cells with the anti-androgen, hydroxyflutamide, results in two new sublines: one (PC346Flu1) with overexpression of the AR and its proliferation suppressed by androgen in vitro was more tumorigenic in castrated than in intact nude mice, whereas the other (PC346Flu2) with the AR(T877A) mutation behaved similarly to LNCaP cells (Marques et al., 2005) . These contrasting results again showed that androgen/AR signals could be either a proliferation stimulator or suppressor in similar human prostate cancer cells.
Disadvantage of using a single human prostate cancer cell line to study prostate cancer progression and metastasis From the results described above, it should be noted that data obtained solely from in vitro studies of human prostate cancer cell lines might not reliably predict the in vivo AR functions in prostate cancer progression and metastasis. For example, PC-3 and PC345DCC cells that either lack AR or with minimal AR have been regarded as androgen-independent cells. It is generally believed that a prostate cancer with this type of cells would not respond to ADT. The results presented in sections 'PC-3 cells: AR functions as suppressor of proliferation and metastasis' and 'PC346C cells: AR functions as proliferation stimulator and suppressor', however, indicate these cells are still capable of responding to stromal AR signals for growth and/or metastasis. Furthermore, PC-3 cells with stable transfection of AR cDNA under different promoters may yield different results on androgen treatment (section 'PC-3 cells: AR functions as suppressor of proliferation and metastasis'). CWR22rv1-AR þ /À cells also had lower in vitro growth rate, yet produced bigger primary and PLN metastatic tumors in vivo than its parental ARpositive CWR22rv1-AR þ / þ cells (section 'CWR22Rv1 cells: AR functions as proliferation stimulator and suppressor').
Finally, several current available human prostate cancer cell lines were generated from long-term culture in the absence of androgen, which may not represent the in vivo human prostate condition based on the reports by Titus et al. (2005) showing that even after ADT treatment, the human prostate tissues still have about 1-3 nM 5a-dihydrotestosterone, which is approximately 10% of the normal level and is still sufficient to elicit AR transactivation.
Together, these contrasting examples clearly point out the importance of conducting in vivo animal studies of prostate tumors to delineate the pathophysiologic functions of AR in prostate cancer progression and metastasis.
AR dual functions in relation to the altered hormone sensitivity in prostate cancer progression during ADT It has been proposed that cancer arises from neoplastic transformation of stem cells (Reya et al., 2001) . Thus, prostate cancer can be considered to derive from neoplastic transformation of prostate stem cells to form prostate cancer stem cells that generate progenitor cells, which then progress sequentially into CK5-positivebasal cells, CK5/CK8-positive-basal intermediate cells, and then CK8-positive luminal cells (Figure 3) (Litvinov et al., 2003) . Recent studies have indicated that prostate cancer progression from prostate cancer stem cells might involve different stem/progenitor cells with different levels of AR expression at different stages with varying proliferation and differentiation potentials (Figure 3) . The distribution of these cells in prostate cancer might vary with patients and tumor stages and thus have different sensitivities toward AR-differential signals and may respond to ADT differentially (see Supplementary Information for more details).
Other possible explanations involving differential AR functions in various prostatic cells to influence hormone sensitivity during ADT include (a) AR somatic mutations, (b) altered interactions between AR and AR coregulators, (c) neuroendocrine differentiation of prostate cancer cells, (d) epithelial-mesenchymal transi-tion (EMT) of prostate cancer cells, (e) development of ligand-independent activation of AR by growth factors or protein kinases, and (f) changes in AR expression between primary and metastatic prostate tumors. All these phenotypic changes undoubtedly would alter androgen/AR signals and affect the outcome of ADT (see Supplementary Information for more detailed descriptions of these changes).
The impact of AR dual functions on current clinical ADT
Challenge to current ADT The fact that the stromal and epithelial ARs have opposite functions to modulate prostate cancer cell proliferation and metastasis undoubtedly is a main challenge for current ADT to treat prostate cancer patients. As ADT suppresses androgens binding to whole body AR, including both the stromal and epithelial AR, its treatment effect would depend on which cell's AR has a more significant function in a given stage of prostate cancer progression. At early stages of prostate cancer when tumors are dependent predominantly on stromal AR-modulated signals for growth and metastasis, ADT would result in regression of the tumor because of increased apoptosis of the tumor epithelial luminal and stromal cells, with much less effect on cancer stem/progenitor cells and some of their transit amplifying progenitors-basal cells (Figure 3 ). Subsequently, prostate cancer stem/progenitor cells and their transit amplifying progenitors/basal cells will adapt to the new AR signals during ADT and develop, either with AR somatic mutations, or altered AR to AR coregulators ratio, or increasing neuroendocrine differentiation, and/or EMT into more aggressive tumors that have different responses to AR signals.
The transition of prostate cancer into a more aggressive phenotype under low androgen conditions has been reported during tumorigenesis in Nkx3.1-Pten mutant mice (Banach-Petrosky et al., 2007) . Continuing suppression of androgen at castration level through ADT would accelerate tumor metastasis because of ablation of the metastasis suppressor function of AR in the basal intermediate cells, thereby resulting in failure of ADT. Consistent with this view is the observation of Kleeberger et al. (2007) that the expression of nestin, a tumor metastasis marker, in prostate cancer cells is associated with ADT, and is mainly detected in refractory tumors while almost undetectable in tumors from patients without ADT.
Target the stromal AR at an early stage It is apparent that ADT will have some beneficial effects on early prostate cancer, but will eventually fail in view of the dual functions of AR signals in prostate cancer (Mercader et al., 2001) and decreased stromal cells, including the cancer-associated fibroblasts (CAF). progression ( Figure 3) . Therefore, it may be better to target the AR at an early stage of prostate cancer when the progression and metastasis of the tumor is predominantly dependent on the stromal AR function. This approach is best exemplified by the timing of inducing ARKO in ind-ARKO-TRAMP mice described in section 'Relative influences of the stromal and epithelial AR on prostate cancer progression and metastasis' (Niu et al., 2008b) . Thus, because of the dual functions of AR, treatment of prostate cancer patients with ADT may have good response during the early stage of cancer, but worsen the prognosis during the later stages of cancer progression when they are less dependent on the stromal AR-modulated signals for growth, a scenario apparently observed in castrated TRAMP mice (Johnson et al., 2005) as well as in ind-ARKO-TRAMP mice after induction of ARKO at an early or late stage (Niu et al., 2008b) . This also explains why some patients can benefit from intermittent treatment with cycles of androgen deprivation and supplementation (Akakura et al., 1993; Crook et al., 1999; Hurtado-Coll et al., 2002) . For example, combined androgen blockade treatment of advanced prostate cancers provided at best a 5% increase in 5-year survival rate over ADT alone (Schmitt et al., 2001 ), but does not cure the disease. On the other hand, therapies aiming at maximal eradication of cancer cells including the cancer stem cells and their progenitors, such as radical prostatectomy and radiation therapy in conjunction with ADT, should provide a better clinical outcome than ADT alone, particularly in localized prostate cancer.
Strategies targeting the tumor stroma (Bouzin and Feron, 2007; Hofmeister et al., 2008) also should be beneficial to prostate cancer patients, as exemplified by the better treatment efficacy of combining therapy with ADT and anti-angiogenic agents targeting the stromalderived vascular factors (Johansson et al., 2007) in the rat Dunning prostate cancer model. Similarly, combining ADT with Trk tyrosine kinase inhibitors targeting the receptor for stroma-derived AR-independent nerve growth factor was reported to prolong tumor regression in the rat prostate cancer model (George et al., 1999) . However, if the disease recurs after these treatments, the adjuvant ADT may still fail because the recurrent tumor may become less dependent on the stromal AR for growth and more invasive because of abrogation of the metastasis suppressor function of the epithelial AR.
Concomitant treatment of AR antagonism with anti-metastasis agents As ADT may promote the development of metastatic prostate tumors, it would be better to combine ADT with anti-metastatic agents or agents capable of suppressing EMT to improve the treatment effect. In metastatic tumors of pes-ARKO-TRAMP and PC-3-v cells, the expression of various tumor metastasis-related genes were significantly changed in favor of invasion and metastasis as compared with the tumors of TRAMP mice and PC-3-AR9 cells, respectively. Thus, several pro-metastasis genes such as cyclooxgenase-2, matrix metaloproteinase-9, interleukin-6, and tumor necrosis factor-a were elevated, whereas anti-metastasis genes such as neutral endopeptidase and the cell cycle inhibitor P27 (Kip1) were decreased in the tumors of pes-ARKO-TRAMP mice and PC-3-v orthotopic grafts compared with the tumors of their AR-expressing counterparts (Niu et al., 2008a) . Part of these effects of AR seemed to be mediated through the suppression of TGFb1, as expression of AR in prostate cancer cells resulted in suppression of TGFb1 expression and overexpression of TGFb1 resulted in increased invasiveness and similarly altered expressions of the metastasisrelated genes mentioned above (Niu et al., 2008a) . Moreover, TGFb1 is known as an inducer of cancer cells to undergo EMT that is linked to the process of metastasis.
As patients with recurrent prostate cancer usually die of metastatic disease, their survival can be extended if tumor metastasis can be delayed or prevented through additional treatment regimens. Treatments targeting metastasis-related activities (Baritaki et al., 2009) or EMT-related genes downstream to the epithelial AR signaling or targeting neuroendocrine factors should improve the clinical results of adjunct ADT. For example, treatments targeting TGFb1 and/or its receptor have been under clinical trial (Pinkas and Teicher, 2006) . In addition, current available agents targeting Akt, COX-2, MMP-9, Vitamin E derivatives, or other relevant anti-metastasis agents in conjunction with ADT as earlier proposed (Miyamoto et al., 2005) may have clinical benefits for patients to battle metastatic prostate cancer, and may represent new treatment strategies to combat this deadly disease.
Future direction: Targeting AR in selective prostate cells
It is apparent that successful treatment of prostate cancer will rely on complete eradication of prostate cancer cells. This treatment objective can be achieved by prostatectomy when the disease is localized. Unfortunately, detection of prostate cancer at such an early stage is less frequent than more advanced diseases. As prostate cancer progresses with continuous interactions among various AR-positive stromal, epithelial, and infiltrating cells within the tumor microenvironment (Figure 3) targeting only those cells (such as stromal and/or luminal cells) with AR functions as positive roles to promote prostate cancer progression may be worthy of development in the future to battle prostate cancer. Recent studies (Yang et al., 2007; Chang et al., paper in preparation) showing ASC-J9 could degrade AR more aggressively in stromal and luminal cells that resulted in suppression of prostate refractory tumors with little side effects or toxicity may shed new light on our hope to treat prostate cancer. Alternatively, developing new nanoparticles carrying anti-AR compounds that only recognize and kill those prostate cells with AR-positive roles will be another new hope in the future.
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